New treatment for kidney problems caused by alcoholic liver disease
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome
This study is testing a new treatment using a supplement called nicotinamide riboside to help improve kidney and liver health in people with hepatorenal syndrome caused by alcoholic liver disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mitopower LLC NIH-funded |
| Lab location | 1 site (Palo Alto, United States) |
| Project ID | NIH-10920469 on NIH RePORTER |
What this research studies
This research investigates a novel therapy aimed at treating hepatorenal syndrome, a serious condition that can occur in patients with alcoholic liver disease. The approach focuses on addressing the cellular dysfunction and inflammation that lead to kidney failure by using a supplement called nicotinamide riboside (NR) to boost levels of a critical molecule known as NAD+. By enhancing mitochondrial function and reducing organ damage, the therapy aims to improve kidney and liver health in affected patients. The research utilizes animal models to evaluate the effectiveness of this treatment before considering human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcoholic liver disease who are experiencing hepatorenal syndrome.
Not a fit: Patients with liver disease not related to alcohol or those without kidney complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from kidney failure related to alcoholic liver disease.
How similar studies have performed: Previous studies have shown promising results with NAD+ supplementation in animal models, indicating potential for success in this novel approach.
Where this research is happening
Palo Alto, United States
- Mitopower LLC — Palo Alto, United States (Active)
Researchers
- Principal investigator: Subramanian, Mani — Mitopower LLC
- Study coordinator: Subramanian, Mani
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.